. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Infect Dis Clin North Am. 2019 Jun;33(2):593–609. doi: 10.1016/j.idc.2019.02.007

Table 3:

Vaccination in Immunocompromised Travelers

Safe to give^b	Unsafe-contraindicated
Hepatitis A^c	Yellow Fever (YFV)^e,f
Intramuscular Typhoid^d	Oral Typhoid
Inactivated Polio (IPV)^e	Oral Polio (OPV)^g
Hepatitis B	Oral Cholera
Meningitis (MCV-4)^,e
Rabies^d
Japanese encephalitis^d

Country and indication specific vaccine recommendations available through the CDC.⁸⁴

Vaccines are injections unless otherwise indicated.

Can also consider Hepatitis A specific immunoglobulin for short-term pre-exposure prophylaxis if unlikely to mount immune response to vaccination

Immunogenicity not known in immunocompromised recipients.

Proof of vaccine receipt may be required for entry to certain destinations. If YFV cannot safely be given, a waiver letter can be granted from certified YFV providers. Risks of disease at destination vs. benefits of travel should be discussed.

Many clinicians remain reluctant to vaccinate with YFV post HSCT regardless of immune status and time elapsed. One recent study demonstrated immunogenicity and safety in a cohort of 21 allogeneic HSCT recipients who were immunized with YFV, a median of 33 months post HSCT.⁸⁵

Not available in US; give IPV